Omecamtiv Mecarbil (OM)

DRUG2 trials

Sponsors

Cytokinetics

Conditions

Heart FailureHeart Failure With Reduced Ejection FractionQT Intervals ChangesQTc Intervals Changes

Phase 1

Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults

CompletedNCT04175808

CytokineticsQTc Intervals Changes, QT Intervals Changes

Start: 2019-11-14End: 2020-03-04Updated: 2025-03-30

Phase 3

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

RecruitingNCT06736574

CytokineticsHeart Failure, Heart Failure With Reduced Ejection Fraction

Start: 2024-12-19End: 2027-12-01Target: 1800Updated: 2026-08-28